UK Weathers Challenges Of COVID-19 And Brexit
BGMA’s Smith Praises Pandemic Response, But Sees Destructive Potential Of Brexit
Executive Summary
Departing BGMA leader Warwick Smith highlights successes in the UK off-patent industry’s response to the COVID-19 pandemic but offers unambiguous criticism of Brexit in the concluding part of an exclusive interview with Generics Bulletin.
You may also be interested in...
UK Could Become ‘World Leader’ On Biosimilar Regulation
The UK is putting itself in a position to play a leading role in global biosimilars regulation, thanks to a proposed new registration pathway that will not require comparative efficacy data, delegates to a Westminster Health Forum online conference heard.
UK Could Become ‘World Leader’ On Biosimilar Regulation
The UK is putting itself in a position to play a leading role in global biosimilars regulation, thanks to a proposed new registration pathway that will not require comparative efficacy data, delegates to a Westminster Health Forum online conference heard earlier today.
Action Needed To Prevent Post-Brexit Catastrophe In Northern Ireland
Action is needed from both the UK government and the European Commission to prevent a collapse of Northern Ireland’s generics market, according to the BGMA.